U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Lymphoid Neoplasm

MedGen UID:
1767996
•Concept ID:
C5419563
•
Neoplastic Process

Definition

A malignant lymphoid neoplasm that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Malignant Lymphoid Neoplasm

Professional guidelines

PubMed

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J
Am J Hematol 2022 Jan 1;97(1):129-148. Epub 2021 Oct 8 doi: 10.1002/ajh.26352. PMID: 34533850
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA
J Interferon Cytokine Res 2019 Jan;39(1):6-21. Epub 2018 Jun 11 doi: 10.1089/jir.2018.0019. PMID: 29889594Free PMC Article

Recent clinical studies

Etiology

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F
Nat Med 2023 Oct;29(10):2593-2601. Epub 2023 Sep 14 doi: 10.1038/s41591-023-02572-5. PMID: 37710005Free PMC Article
Diffuse Large B-Cell Lymphoma.
Sehn LH, Salles G
N Engl J Med 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296Free PMC Article
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396
Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Raderer M, Kiesewetter B, Ferreri AJ
CA Cancer J Clin 2016 Mar-Apr;66(2):153-71. Epub 2015 Nov 24 doi: 10.3322/caac.21330. PMID: 26773441

Diagnosis

Pure red cell aplasia: The second hundred years.
Means RT Jr
Am J Med Sci 2023 Sep;366(3):160-166. Epub 2023 Jun 14 doi: 10.1016/j.amjms.2023.06.009. PMID: 37327996
Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A, Rezvani K
Int J Hematol 2021 Nov;114(5):554-571. Epub 2021 Aug 28 doi: 10.1007/s12185-021-03209-4. PMID: 34453686Free PMC Article
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396
Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Raderer M, Kiesewetter B, Ferreri AJ
CA Cancer J Clin 2016 Mar-Apr;66(2):153-71. Epub 2015 Nov 24 doi: 10.3322/caac.21330. PMID: 26773441

Therapy

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, Liu Y, Li Q, Inamdar A, Beer T, Tang HY, Perkey E, Maillard I, Bonasio R, Shi J, Ruella M, Wan L, Busino L
Blood 2023 Sep 14;142(11):973-988. doi: 10.1182/blood.2022018752. PMID: 37235754Free PMC Article
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P
Blood 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. PMID: 37130017Free PMC Article
Epigenetic targeting in lymphoma.
Booth S, Collins G
Br J Haematol 2021 Jan;192(1):50-61. Epub 2020 Jul 1 doi: 10.1111/bjh.16914. PMID: 32609383
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.
Lunning MA, Vose JM
Blood 2017 Mar 2;129(9):1095-1102. Epub 2017 Jan 23 doi: 10.1182/blood-2016-09-692541. PMID: 28115369
Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Raderer M, Kiesewetter B, Ferreri AJ
CA Cancer J Clin 2016 Mar-Apr;66(2):153-71. Epub 2015 Nov 24 doi: 10.3322/caac.21330. PMID: 26773441

Prognosis

Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Acute lymphoblastic leukaemia.
Malard F, Mohty M
Lancet 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PMID: 32247396
Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H, Kantarjian HM, Jabbour EJ
Leuk Lymphoma 2019 Nov;60(11):2606-2621. Epub 2019 May 16 doi: 10.1080/10428194.2019.1605071. PMID: 31092071
Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Raderer M, Kiesewetter B, Ferreri AJ
CA Cancer J Clin 2016 Mar-Apr;66(2):153-71. Epub 2015 Nov 24 doi: 10.3322/caac.21330. PMID: 26773441
Myelodysplastic/myeloproliferative neoplasms.
Cazzola M, Malcovati L, Invernizzi R
Hematology Am Soc Hematol Educ Program 2011;2011:264-72. doi: 10.1182/asheducation-2011.1.264. PMID: 22160044

Clinical prediction guides

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H
Lancet Haematol 2023 Jan;10(1):e24-e34. Epub 2022 Nov 16 doi: 10.1016/S2352-3026(22)00319-2. PMID: 36402146
Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma.
Nowakowski G, Maurer MJ, Cerhan JR, Dey D, Sehn LH
Am J Hematol 2023 Jan;98(1):180-192. Epub 2022 Oct 31 doi: 10.1002/ajh.26767. PMID: 36251361Free PMC Article
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL
Lancet Oncol 2022 Aug;23(8):1055-1065. Epub 2022 Jul 5 doi: 10.1016/S1470-2045(22)00335-7. PMID: 35803286
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
The Role of PI3K Inhibition in Lymphoid Malignancies.
von Keudell G, Moskowitz AJ
Curr Hematol Malig Rep 2019 Oct;14(5):405-413. doi: 10.1007/s11899-019-00540-w. PMID: 31359259

Recent systematic reviews

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review.
Ridwansyah H, Wijaya I, Bashari MH, Sundawa Kartamihardja AH, Hernowo BS
Biomol Biomed 2023 Sep 4;23(5):727-739. doi: 10.17305/bb.2023.8791. PMID: 37004241Free PMC Article
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis.
Liu H, Xi R, Mao D, Zhao X, Wu T
Clin Lymphoma Myeloma Leuk 2023 Mar;23(3):e139-e149. Epub 2022 Dec 17 doi: 10.1016/j.clml.2022.12.009. PMID: 36593170
Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M, Jacob I, Nikoglou T, Connors JM
Br J Haematol 2020 Feb;188(4):540-549. Epub 2019 Oct 6 doi: 10.1111/bjh.16201. PMID: 31588564Free PMC Article
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M
J Oncol Pharm Pract 2016 Oct;22(5):666-78. Epub 2015 Aug 28 doi: 10.1177/1078155215603230. PMID: 26320127
Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M
Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):199-207. Epub 2014 Oct 2 doi: 10.1016/j.clml.2014.09.008. PMID: 25445467

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...